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Background. We examined overall and disease-free survivals in a cohort of patients subjected to resection of liver metastasis
from colorectal cancer (CRLM) in a 10-year period when new treatment strategies were implemented. Methods. Data from 239
consecutive patients selected for liver resection of CRLMduring the period from 2002 to 2011 at a single center were used to estimate
overall and disease-free survival. The results were assessed against new treatment strategies and established risk factors. Results.
The 5-year cumulative overall and disease-free survivals were 46 and 24%. The overall survival was the same after reresection,
independently of the number of prior resections and irrespectively of the location of the recurrent disease. The time intervals
between each recurrence were similar (11 ± 1 months). Patients with high tumor load given neoadjuvant chemotherapy had
comparable survival to those with less extensive disease without neoadjuvant chemotherapy. Positive resectionmargin or resectable
extrahepatic disease did not affect overall survival.Conclusion. Our data support that one still, and perhaps to an even greater extent,
should seek an aggressive therapeutic strategy to achieve resectable status for recurrent hepatic and extrahepatic metastases. The
data should be viewed in the context of recent advances in the understanding of cancer biology and the metastatic process.
1. Introduction
The incidence of colorectal cancer (CRC) is increasing and
is now the fourth leading cause of cancer deaths worldwide
[1]. Twenty percent of the patients present with synchronous
livermetastases and another 30–40%develop livermetastases
during followup [2]. Hepatic resection remains the only
potentially curable treatment and is now offered to 20–
25% of the patients whereas only 10% were selected for this
treatment ten years ago [3]. The main exclusion criteria
for liver resection of colorectal liver metastases (CRLMs)
are nonresectable liver metastasis (tumor growth into both
portal branches and/or into both left and right liver vein),
inadequately functioning residual liver parenchyma, or non-
resectable extrahepatic disease. These exclusion criteria have
all been challenged in recent years. Close followup after
primary CRC (early detection ofmetastasis), implementation
of new surgical techniques including two-stage hepatectomy
with portal vein embolization [4, 5] and transplantation
methods, and the introduction of new chemotherapy and
biological agents capable of converting inoperable cases to
a resectable status by tumor downsizing have increased the
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number of patients eligible for resection of livermetastases [6,
7]. As a consequence, reresection of patients with recurrent
disease is now offered to an increasing number of selected
patients [8, 9].
A cohort of 239 patients with CRC and synchronous
or metachronous CRLMs eligible for liver resection with
curative intent was followed from 2002 to 2011. The aim of
the study was to examine overall and disease-free survivals
related to number of resections, therapeutic downsizing,
surgical technique, and other factors considered to have
prognostic value.
2. Patients and Methods
2.1. Patients Selection and Management. All patients were
considered preoperatively by a multidisciplinary team. The
assessment included computed tomography (CT) of the
abdomen and chest with the addition of magnetic resonance
(MR) or ultrasonography with contrast when resectabil-
ity could not be determined after CT. Positron emission
tomography (PET) became available in 2009 and was used
to assess extrahepatic disease in selected cases. Intraoper-
ative contrast-enhanced ultrasonography (CEU) was used
in every procedure after 2007 to assess resectability and
tumor expansion as previously described [10]. Preoperative
carcinoembryonic antigen (CEA) levels were determined in
all patients in the most recent 5-year period.
The Brisbane terminology was applied to classify the
liver resections [11]. Laparoscopic resection was introduced
during the last 4-year period for selected patients with
small, subcapsular lesions or lesions in the lateral or lower
segments (segments II, III, IVb, V, and VI). The term two-
stage hepatectomy was used where the first surgical step
included nonanatomical resection on one side combinedwith
postoperative portal vein embolization of the most affected
side, followed by a second step with formal resection of the
side with remaining disease.
2.2. Data Collection and Statistics. Information was retrieved
from medical records, including operation, radiology, and
pathology reports. Followupwas performed in our outpatient
clinic at 4, 8, and 12 months and from the second postop-
erative year at 6-month intervals for a total of 5 years. Size
of the largest tumor and number of metastases were used to
compare tumor load between subgroups and the tumor load
was calculated by points based on the worst score for each
parameter in the Basingstoke Predictive Index (8 points if
diameter of the largest tumor >10 cm; adapted to 8 points/cm
and 4 points if >3 metastases; adapted to 1 point/number of
metastases andmultiplied by 10 to produce a score where size
and load are equally representative). We assessed our results
against established risk factors reported by others [12–14] (see
supplemental Figure S1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2013/727095).
Filemaker Pro 9.0 (Santa Clara, CA, USA) was used
to register data that were analyzed in SPPS 16.0 (Chicago,
IL, USA). Graphs were made in SigmaPlot 11.0 (San Jose,
CA, USA). Kaplan-Meier plots and log-rank (Mantel-Cox)
comparisons were used to compute cumulative survival data.
Pearson’s chi-square test was used to compare ratios. Group
means were compared using Student’s t-test if the variables
passed a normality test; otherwise medians where compared
with rank-sum test. The study and database were approved
by the Oslo University Hospital Data Protection Officer for
Research.
3. Results
Patients undergoing surgery for CRLMs (adenocarcinoma)
were registered partly prospectively andpartly retrospectively
in a database from October 2002 to August 2011. In the study
period, a total of 268 patients were initially included.Of these,
27 patients were deemed inoperable intraoperatively due
to extensive hepatic or extrahepatic metastatic disease and
excluded from the study. Five of these patientswere scheduled
for two-stage hepatectomy [15] but were inoperable at the 2nd
surgical step. In addition, two patients in the original database
received liver transplants [16] and were excluded resulting in
a total of 239 patients analyzed in the present study.
The cohort of 239 patients with metastatic colorectal
cancer patients resected for liver metastasis was examined
for overall and disease-free survivals. Characteristics of the
patient cohort and primary tumor are presented in supple-
mental Table S1.
3.1. Liver Resection. Liver resection of the CRLMs was suc-
cessfully accomplished in 90.7% (𝑛 = 214) of the planned
single-stage procedures and in 83.3% (𝑛 = 25) of the planned
two-stage procedures (mean age 64.3 years, range 26–89
years; 118 females; Table 1). A total of 353 surgical procedures
were registered in the cohort, representing primary resections
(𝑛 = 239), secondary resections (𝑛 = 65), and tertiary
resections (𝑛 = 21); 2nd step of two-stage hepatectomy
(𝑛 = 25) and 2nd step of single-stage surgery converted to
two-stage without embolization (𝑛 = 3; see supplemental
Table S2 for details of the surgical procedures). In 16 patients
with rectum cancer (after 2008), a liver-first approach was
chosen [17]. The type of resection and details are presented
in supplemental Table S2.
3.2. Overall andOncologicOutcome. Intraoperativemortality
was zero; however three (1.3%) died within 30 days after
the surgical procedure (day 17, 29, and 29, resp.). At a
median observation time of 24 months (range 1–108 months
by October 2011) 99 of the 239 patients (41.1%) were alive
and disease-free, and 64 (26.8%) of the patients were alive
with recurrent disease and were currently receiving palliative
treatment or were undergoing evaluation for re-resection.
Furthermore, 66 of the patients (27.6%) had died of the
disease and 10 (4.2%) had died of unrelated reasons or
of unknown cause. The cumulative overall 5- and 9-year
survivals were 46.0 and 34.9%, respectively, and comparable
to that of other centers (36 to 58% and 23 to 36% for 5- and
10-year survivals, respectively [12, 13, 18–23]). The disease-
free survivals were 24.0 and 20.0% for 5- and 7-year follow-up
periods, respectively (Figure 1(a)). The locations of recurrent
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Table 1: Characteristics of liver metastases.
Value
Age (range) 64.3 (26–89)
Female/male 118/121
BPI score (range) (𝑛 = 94) 5.98 (0–27)
Metachronous/synchronous metastases 133/106
Number of tumors in the liver
1/2/3/4/5/6 or more 87/52/31/14/12/18
Missing 25
Size diameter mm (mean/median/min/max) 29/22/2/155
Missing 15
Number of segments involved
1/2/3/4/5/6 or more 63/70/40/29/13/6
Missing 18
CEA (𝑛 = 140) 55.5 (0.7–1400.0)
Extra hepatic disease 19
Neoadjuvant chemotherapy
Yes/no/na 112/127/0
Adjuvant chemotherapy
Yes/no/na 128/89/22
disease are presented in supplemental Table S3 and show a
shift in target organ as the disease continues to recur.
3.3. Resection of Recurring Metastases. In the observation
period 146 patients presented with a second recurrent disease
and surgery with curative intent was performed in 65 (44.8%)
of them. A third recurrent disease presented in 69 patients
and surgery with curative intent was performed in 21 (30.4%).
Overall survival appeared to be the same after the first,
second, and third resections and the disease-free survival was
similar in the groups resected once and twice (Figure 1(a)).
Furthermore, survival after the second resection was compa-
rable independently of whether the location of the recurrent
disease was to the liver, lung, or elsewhere (Figure 1(b) and
supplement Table S3). The average time from surgery of
the primary tumor to resection of the first CRLM was 11.7
months; the average time from surgery for the CRLM to the
presentation of a second recurrent disease (irrespective of
localization) was 10.1 whereas themean time from the second
to the third recurrence was 11.0 months.
3.4. Downsizing and Neoadjuvant Chemotherapy. Preopera-
tive (neoadjuvant) chemotherapy was given to 46.9% of the
patients (𝑛 = 112, Table 1). The indications for neoadjuvant
chemotherapy changed during the study period. In the first 5-
year period (2002–2006, 𝑛 = 24; 32.9%), neoadjuvant therapy
was primarily given to nonresectable patients. In the last 5-
year period (2007–2011, 𝑛 = 88; 53.0%), the indications were
broader and included patients with high tumor load (3 or
more metastases or large metastasis above 30mm (diameter)
or synchronous metastases) and from January 2010 young
patients with elevated CEA and ECOG performance status
0-1 [24]. The cumulative overall 5-year survival of patients
receiving neoadjuvant chemotherapy was 36.1% versus 52.6%
in the nonneoadjuvant group (𝑃 = 0.008) whereas survival
between the two groups appeared similar during past 80
months (Figure 2(a)). The 5-year disease-free survival was
21.0% in the neoadjuvant group versus 26.5% in the non-
neoadjuvant group (𝑃 = 0.025). Tumor load was significantly
higher in the neoadjuvant group (Figure 2(a), insert).
Stratification of neoadjuvant chemotherapy combined
with tumor load revealed that the survival in patients
with high tumor load receiving preoperative chemotherapy
was increased compared to that of patients not receiving
chemotherapy. In contrast, patients with low tumor load who
did not receive neoadjuvant chemotherapy had increased
survival compared to the survival of those who received
chemotherapy.
3.5. Two-Stage Hepatectomy. Thirty patients received two-
stage hepatectomy from 2008 due to bilateral disease. Five of
them (16.7%) were inoperable at the second surgical step and
excluded from the study and results. Patients selected for two-
stage hepatectomy had a higher risk of developing recurrence
as all patients in this group presented with recurrent disease
within 2 years compared to a 60.7% recurrence in patients
subject to a single-stage procedure in the same time interval
(Figure 2(b)). Nonetheless, the overall survival in the group
that received two-stage hepatectomy appeared comparable to
that of the single-stage procedure group with the limited data
available. Of the 25 patients who underwent the two-stage
procedure, six (24.0%) were alive with a mean observation
time of 17 months (range 6–45) and were reported to be
disease-free at the time of examination of the cohort.
3.6. Laparoscopic Surgery. Since the introduction of laparo-
scopic resection in 2008, 60 patients have been selected
for this procedure of which 48 were successfully completed
(20.0% conversion rate). In addition, the first step of planned
two-stage surgery was performed laparoscopically in two
patients. Patients selected for a laparoscopic approach had
a better outcome than patients selected for open surgery
(Figure 2(c)) and lower tumor load (insert).
3.7. Prognostication of Colorectal Liver Metastasis. Primary
tumor lymph node status, histological differentiation grade,
synchronous or metachronous disease, tumor size (metas-
tasis), numbers of metastases, affected liver segments, and
CEA levels turned out to be prognostic markers affecting
survival (supplemental Figure S1). Furthermore, we found
ascending age to be a positive prognostic marker for disease-
free survival (Figure 3(a)). In contrast, examining the over-
all survival, we observed an apparent higher mortality in
the older patient group. Extrahepatic disease (𝑛 = 19,
Figure 3(c)) and positive hepatic resection margin (R1/R2,
𝑛 = 31, Figure 3(b)) impaired disease-free survival. However,
overall survival was not affected by resectable extrahepatic
disease or positive resection margins.
In the present material, men had better overall outcome
and rectum cancer correlated positively with overall and
disease-free survivals (supplemental Figure S1a and b).
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Figure 1: Overall and disease-free survivals of colorectal cancer patients following liver resection of primary or recurring metastasis. (a)The
Kaplan-Meier plots showing overall (full line) and disease-free (dashed line) survivals in the total population and after the first, second, and
third resections. +: censored cases. (b) Survival after a second resection of colorectal metastases at different locations (67 procedures in 65
patients; one patient resected for liver and lung; one patient resected for liver and lymph recurrent disease), data presented as in (a).
4. Discussion
Surgical treatment of CRLMs is offered to an increasing num-
ber of patients with metastatic CRC [3].This has opened sev-
eral new avenues in the treatment of this patient group, and as
a consequence fundamental questions in tumor biology and
clinical strategies are now being challenged. Recent reports
on survival following re-resection of CRLMs and resection of
extrahepatic metastases support a more aggressive treatment
practice [8, 25–27]. Neoadjuvant chemotherapy to downsize
CRLMs increases the number of resectable cases and provides
the opportunity to target a larger patient population. In the
present study patients who received neoadjuvant chemother-
apy to downsize CRLMs reached a long-term overall survival
comparable to that of primary resectable patients, despite
widespread disease. It is, in this connection, important to
note that tumor load calculations were performed based
on information in the pathology reports and are there-
fore postneoadjuvant chemotherapy which means that they
underreport the initial tumor load.
Here we report that second and third resections of recur-
ring CRLMs should be considered when possible and that
resection also should be assessed in patientswith extrahepatic
recurrences as their prognosis does not appear to be worse,
but for strict recommendations randomized clinical trials
would be needed. Patients selected for laparoscopic approach
had a better outcome than patients selected for open surgery
(Figure 2(c)), which may be related to the selection criteria
and tumor load. A recent report indicates laparoscopic results
comparable to those of open surgery when the selection
criteria are identical for the two procedures [28]. Females are
reported to have a better prognosis after liver resection for
CRLMs thanmales and colon cancer to have better prognosis
than rectum cancer [14]. However, in the present material,
men had better overall outcome and a primary rectum cancer
correlated positively with overall and disease-free survivals
(supplemental Figure S1a and b). The latter may reflect
observations that neoadjuvant radiochemotherapy and a
more radical surgical technique, total mesorectal excision
(TME), have improved survival after treatment for rectum
cancer. Ascending age has been reported to be both negatively
and positively correlated with survival [12, 14, 29]. We found
ascending age to be a positive prognostic marker for disease-
free survival (Figure 3(a)), which may be related to more
aggressive tumor biology in younger patients. A higher
proportion of the young patients presented with recurrent
disease and the recurrence occurred more rapidly than in
older patients. Interestingly, the overall survival curves were
inverted compared to disease-free survival with respect to the
different age groups (Figure 3(a)).This could be explained by
increased surgical and adjuvant efforts towards young and
otherwise healthy patients. If this is the case, this in itself
could be proof that an aggressive approach could produce
long-term survivors.
Recent genetic andmolecular studies ofmetastaticmalig-
nant disease indicate that metastases often develop in parallel
to the primary tumor from an early stage, and that the tumor
biology of the metastases is not necessarily more aggressive
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Figure 2: Overall and disease-free survivals after neoadjuvant chemotherapy and the first resection for colorectal metastases (a), after two-
stage hepatectomy with portal vein embolization (b), or after laparoscopic surgery (c). Data presented as in Figure 1(a). Bar charts (top left
corners) show mean tumor load score calculated as indicated in the Patients and Methods section. Independent t-test was used to compare
mean tumor load in subgroups.
than that of the primary tumor [30, 31]. Previous studies
addressing the growth rate of various malignant tumors
including CRC indicate that the tumor volume doubling time
(TVDT) of the metastases is comparable to that of the pri-
mary tumor [32]. This may suggest that metastases identified
late and removed in re-resection procedures could represent
tumors that were not recognized at the time of surgery of
the primary tumor or the first metastasis due to their small
size, rather than progressively developing and increasingly
aggressive metastases. In our cohort, this may be reflected in
the observation that overall survival and oncologic outcome
were comparable in patients with successful outcome of the
first resection and those who required a second or third
resection. In line with this thinking, “recurrent disease” may
be a misnomer as the disease may not be recurring but
continues to deliver earlier established metastases growing in
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Figure 3: Overall and disease-free survivals stratified on risk factors. Data presented by the Kaplan-Meier plots with overall (solid line) and
disease-free (dashed line). Age group (a), hepatic resection margin (b), and extrahepatic disease at the time point of surgery, as indicated.
parallel and reaching a size that allows diagnosis at different
time points following the primary surgery. Thus, resection of
metastases may in many cases represent incremental tumor-
reductive surgery rather than treatment of recurrent disease.
Thismay also help to explain why the discrimination between
R0 andR1/R2 resections of CRCmetastases is not crucial with
respect to overall survival (our data and [33]). These findings
are in contrast to expected results from current scoring
systems [12, 14]. In conclusion, metastatic disease is systemic
or multifocal in its nature and may encompass unrecognized
foci at the time of surgery in most if not all patients
irrespectively of the presentation at diagnosis. Eradication
of all tumor tissue may therefore not be conceivable in the
majority of the patients. However, this recognition should
not preclude an aggressive treatment approach with repeated
resections that continue to reduce tumor load.
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Extrahepatic metastatic spread has previously been con-
sidered an end-stage disease. In recent years, however, com-
bined liver and lung resections have produced long-time
survivors. Consequently, pulmonary metastasis alone is no
longer considered an exclusion criterion for surgery [34].
Six patients in our cohort presented with concomitant pul-
monary lesions with uncertainmalignant potential; resection
of CRLMs was performed with a “wait and watch” approach
taken with respect to the development of pulmonary metas-
tases. In four patients the pulmonary metastases progressed
but were accessible by lung resection and three of these
were alive and had remained disease-free until the time of
examination of the cohort. It is also interesting to observe
that patients resected for recurrent disease to the lung after
first having performed hepatic resection had comparable and
maybe even better survival compared to those repeatedly
resected for recurrent disease in the liver, and as such,
pulmonary metastases may not be a sign of an explosive
metastatic spread [35].
5. Conclusion
The presented results indicate that surgical treatment, when
possible with or without neoadjuvant treatment, significantly
prolongs life and may in some cases cure the disease,
even when extensive. Hence, efforts to identify or induce
technically resectable cases are crucial and include early
detection of metastatic spread, improved surgical techniques,
and neoadjuvant chemotherapy to downsize the metastases.
Patients that become resectable after neoadjuvant therapy
appear to reach the same survival rate as that of as patients
that are primary resectable. Furthermore, neoadjuvant ther-
apy may also be used for selection of patients with the best
prognosis after surgical resection, as patients that progress
during ongoing treatment will probably not benefit from
surgical treatment. The present report adds to the current
knowledge base of the outcome of an aggressive treatment
approach to metastatic CRC. Although metastatic CRC has
a poor prognosis, surgical treatment has clear patient benefit
and strategies to make patients resectable and available for
surgery should be pursued.
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